Biomedical subjects

E M Cornford

Publications and source records attributed to E M Cornford.

At least 19 recordsLinked to original sources

PubMed1995

Down-regulation of blood-brain glucose transport in the hyperglycemic nonobese diabetic mouse.

The intracarotid injection method has been utilized to examine blood-brain barrier (BBB) glucose transport in hyperglycemic (4-6 days) mice. In anesthetized mice, Brain Uptake Indices were measured over a range of glucose concentrations from 0.010-50 mmol/l; glucose uptake was found to be saturable and kinetically characterized. The maximal velocity (Vmax) for glucose transport was 989 +/- 214 nmol.min-1.g-1. and the half-saturation constant estimated to be 5.80 +/- 1.38 mmol/l. The unsaturated Permeability Surface area product (PS) is = 171 + 8 microliters.min.-1.g-1. A rabbit polyclonal antiserum to a synthetic peptide encoding the 13 C-terminal amino acids of the human erythrocyte glucose transporter immunocytochemically confirmed the presence of the GLUT1 isoform in non-obese diabetic (NOD) mouse brain capillary endothelia. These studies indicate that a down-regulation of BBB glucose transport occurs in these spontaneously hyperglycemic mice; both BBB glucose permeability (as indicated by PS product) and transporter maximal velocity are reduced (in comparison to normoglycemic CD-1 mice), but the half-saturation constant remains unchanged.

Animals↗

PubMed1995

High expression of the Glut1 glucose transporter in human brain hemangioblastoma endothelium.

The principal glucose transporter at the blood-brain barrier is Glut1, and GLUT1 expression is downregulated in high grade gliomas. In the present study, glucose transporter expression was studied in surgically resected hemangioblastoma tissue. Light microscopic immunochemistry indicated the high expression of the Glut1 glucose transporter isoform throughout the central vascular endothelium of this tissue. Glial fibrillary acidic protein (GFAP) was observed only at the tumor border, with no GFAP immunoreactivity in stromal cells, pericytes or endothelia in the central tumor regions. It is generally believed that more Glut1 is found in erythrocytes than any other cell, but quantitative electron microscopic immunogold analyses of Glut1-immunoreactive sites per micron of capillary membrane showed the Glut1 density in tumor endothelial membranes glucose transporter was 2-3-fold higher than in human red cells. In the same tissue samples, qualitative immunogold electron microscopy of human serum albumin indicated that this protein (MW 65,000) moved freely from the vascular space into pericapillary regions, confirming the leaky barrier characteristics of the hemangioblastoma. These studies show that Glut1 expression may be high in endothelia that are highly permeable and devoid of astroglial contacts. Thus, human cerebral hemangioblastomas may provide a novel system for studying the induction of Glut1 in the blood-brain barrier.

Adult↗

PubMed1994

Developmental modulation of blood-brain-barrier glucose transport in the rabbit.

Blood-brain barrier (BBB) glucose transport rates were measured using the intracarotid injection method in newborn, 14-day-old suckling, 28-day-old weanling and adult rabbits, and compared with membrane transporter density. Light microscope immunochemistry confirmed the presence of the GLUT1 glucose transporter isoform in these rabbits. Quantitative electron microscopic immunogold analyses of GLUT1-immunoreactive sites per micrometer of capillary membrane indicated GLUT1 density increased with age, and correlated with in vivo measurements of Vmax. Maximal transport velocities (Vmax) of glucose transfer (an indicator of the activity and relative number of transporter proteins) increased significantly (P = 0.05) with age: in neonates Vmax = 0.61 mumol.min-1.g-1, in sucklings Vmax = 0.68 mumol.min-1.g-1, in weanlings Vmax = 0.88 mumol.min-1.g-1, and in adults Vmax = 1.01 mumol.min-1 g-1. Cerebral blood flow (CBF) rates, increased with age from 0.19 and 0.26 ml.min-1.g-1 in neonates and sucklings to 0.51 (weanlings) and 0.70 (adults) ml.min-1.g-1. Non-linear regression analyses indicated the half-saturation constant (Km) for glucose transport ranged from 13 mM in adult rabbits to 19 mM in 14-day-old sucklings: differences in Km were not significant. Age-related changes in the Permeability-Surface Area product (PS +/- S.E.) of both water and glucose were also seen. At all ages studied, the diffusion component (Kd) of glucose uptake was not distinguishable from zero. We conclude developmental up-regulation of the rabbit BBB glucose transporter is characterized by no changes in transporter affinity, and provide the first demonstration of increased membrane transporter proteins correlating with an age-related increase (65%) in glucose transporter maximal velocity.

Aging↗

PubMed1994

The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia.

Immunogold electron microscopy was used to examine human brain resections to localize the GLUT1 glucose transporter. The tissue examined was obtained from a patient undergoing surgery for treatment of seizures, and the capillary profiles examined had characteristics identical to those described previously for active, epileptogenic sites (confirmed by EEG analyses). A rabbit polyclonal antiserum to the full-length human erythrocyte glucose transporter (GLUT1) was labeled with 10-nm gold particle-secondary antibody conjugates and localized immunoreactive GLUT1 molecules in human brain capillary endothelia, with < 0.25% of the particles beyond the capillary profile. Erythrocyte membranes were also highly immunoreactive, whereas macrophage membranes were GLUT1-negative. The number of immunoreactive sites per capillary profile was observed to be 10-fold greater in humans than in previous studies of rat and rabbit brain capillaries. In addition, half of the total number of immunoreactive gold particles were localized to the luminal capillary membrane. We suggest that the blood-brain barrier GLUT1 glucose transporter is up-regulated in seizures, and this elevated transporter activity is characterized by increased GLUT1 transporters, particularly on the luminal capillary membranes. In addition, acute modulation of glucose transporter activity is presumed to involve translocation of GLUT1 from cytoplasmic to luminal membrane sites, demonstrable with quantitative immunogold electron microscopy.

Blood-Brain Barrier↗

PubMed1993

An electron microscopic immunogold analysis of developmental up-regulation of the blood-brain barrier GLUT1 glucose transporter.

Electron microscopy was used to quantitate blood-brain barrier (BBB) glucose transporters in newborn, 14-day-old suckling, 28-day-old weanling, and adult rabbits. A rabbit polyclonal antiserum to a synthetic peptide encoding the 13 C-terminal amino acids of the human erythrocyte glucose transporter (GLUT1) was labeled with 10-nm gold particle-secondary antibody conjugates and localized immunoreactive GLUT1 molecules in rabbit brain capillary endothelia. Three distinct populations of brain capillary profiles were identified in newborn rabbits: prepatent capillary buds, partially patent capillaries with highly amplified luminal membranes, and patent capillaries. Immunogold analyses indicated that the GLUT1 transporter abundance positively correlated with capillary developmental status. The mean number of gold particles per capillary profile increased at each developmental age examined, suggesting that developmental up-regulation of the BBB glucose transporter occurred in rabbits. GLUT1 immunoreactivity was three- to fourfold greater on the abluminal than luminal capillary membranes among all ages examined. Changes in the proportions of GLUT1 transporter were also seen, and possible reasons for the postnatal decrease in the percentage of cytoplasmic GLUT1 transporter are discussed. The numbers of cytoplasmic and membrane-associated immunogold particles increased with age. We conclude that regulatory modulations of BB glucose transport may be characterized by increases in BBB glucose transporter density with age and state of development. In addition, modulation of glucose transporter activity may be reflected by minor postnatal shifts of GLUT1 from cytoplasmic to membrane compartments, which can be demonstrated with quantitative immunogold electron microscopy.

Aging↗

PubMed1992

Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain.

Melphalan, a nitrogen mustard derivative of the neutral amino acid L-phenylalanine, was transported across the rat blood-brain barrier by the large (L-system) neutral amino acid transporter in tumor-bearing brain, but no evidence for blood-brain barrier transport by the alanine-serine-cysteine system carrier was obtained in the present study. The ability of melphalan to inhibit phenylalanine uptake was compared in rats implanted with two experimental CNS tumors: the C-6 glioma (a model of primary brain tumors) and Walker carcinoma (a model of metastatic brain tumors). The melphalan concentration which caused 50% inhibition of blood-brain barrier (BBB) phenylalanine uptake (Ki) was 0.49 +/- 0.18 mM in the Walker tumor, compared with 0.46 +/- 0.19 mM in the contralateral control brain. In the ipsilateral hemisphere (Ki = 0.59 +/- 0.25 mM) and contralateral hemisphere (Ki = 0.45 +/- 0.19 mM), drug entry was also via the neutral amino acid transporter. In C-6 gliomas (Ki = 0.77 +/- 0.20 mM) and contralateral control brain (Ki = 0.84 +/- 0.29 mM), melphalan also inhibited BBB phenylalanine transport. A major finding was that, at melphalan concentrations greater than 1.0 mM, BBB permeability of radiolabeled indium (chelated to EDTA) increased in proportion to melphalan concentration. In the contralateral hemisphere of rats implanted with C-6 gliomas, brain extractions of indium-EDTA measured 3 to 4% in the absence of drug, 5 to 6% at 2.5 mM melphalan, and 9 to 10% at 5 mM melphalan. A similar phenomenon was observed in the nontumoral brain regions of rats implanted with Walker carcinoma cells. In normal (nonimplanted) rats, melphalan's inhibition (Ki = 0.29 mM) of phenylalanine and tryptophan (Ki = 0.20 mM) uptake was confirmed, and brain extraction of sucrose (a nonspecific marker which does not penetrate the intact BBB) was observed to increase in proportion to melphalan concentration. We conclude that melphalan not only enters the brain via the neutral amino acid transporter, but at higher concentrations (greater than 1 mM) may open the blood-brain barrier in a nonspecific manner.

Amino Acid Transport Systems↗

PubMed1992

Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.

The blood-brain barrier penetration of amsacrine and its analogs 9-([2-methoxy-4-[(methylsulfonyl)-amino]phenyl]amino)-,5-dimethyl- 4-acridine carboxamide (CI-921) and M-[2-(dimethylamino)ethyl]-acridine-4-carboxamide (AC) was measured in the barbiturate-anesthetized mouse. After intracarotid administration, AC was almost completely extracted (90%) in a single transit through the brain capillaries, whereas CI-921 (20%) and amsacrine (15%) were moderately extracted. AC is retained in the brain; no loss of AC from the brain was apparent at 1, 2, 4, or 8 min after injection. In contrast, after intraportal administration, 75% of the AC, 94% of the CI-921, and 57% of the amsacrine was extracted in a single transit through the hepatic vasculature. Rather than being retained in the mouse liver, these acridine antitumor agents show time-dependent loss (t1/2 = 10 min for amsacrine and AC, 24 min for CI-921). We conclude that unlike most antitumor agents, these acridine drugs appear to penetrate the blood-brain barrier readily.

Acridines↗

PubMed1992

Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.

The pharmacokinetics, tissue distribution and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide(AC) were studied after i.v. administration to mice. Over the dose range of 9-121 mumol/kg (3-40 mg/kg), AC displayed linear kinetics with the following model-independent parameters: clearance (C), 21.0 +/- 1.9 1 h-1 kg-1; steady-state volume of distribution (Vss), 11.8 +/- 1.4 l/kg; and mean residence time (MRT), 0.56 +/- 0.02 h. The plasma concentration-time profiles for AC fitted a two-compartment model with the following parameters: Cc, 19.4 +/- 2.3 1 h-1 kg-1; Vc, 7.08 +/- 1.06 l/kg; t1/2 alpha 13.1 +/- 3.5 min; and t1/2Z, 1.60 +/- 0.65 h. AC displayed moderately high binding in healthy mouse plasma, giving a free fraction of 15.9%-25.3% over the drug concentration range of 1-561 microM. After the i.v. administration of 30 mumol/kg [3H]-AC, high radioactivity concentrations were observed in all tissues (especially the brain and kidney), showing a high t1/2c value (37-59 h). At 2 min (first blood collection), the AC concentration as measured by high-performance liquid chromatography (HPLC) comprised 61% of the plasma radioactivity concentration (expressed as AC equivalents/l). By 48 h, 73% of the dose had been eliminated, with 26% and 47% of the delivered drug being excreted by the urinary and faecal routes, respectively; less than 1% of the total dose was excreted as unchanged AC in the urine. At least five distinct radiochemical peaks were distinguishable by HPLC analysis of plasma extracts, with some similar peaks appearing in urine. The 121-mumol/kg dose was well tolerated by mice, with sedation being the only obvious side effect and no significant alterations in blood biochemistry or haematological parameters being recorded. After receiving a dose of 152 mumol/kg, all mice experienced clonic seizures for 2 min (with one death occurring) followed by a period of sedation that lasted for up to 2 h. No leucopenia occurred, but some mild anaemia was noted. There was no significant change in blood biochemistry. A further 20% increase in the i.v. dose (to 182 mumol/kg) resulted in mortality, with death occurring within 2 min of AC administration.

Acridines↗

PubMed1992

Transport of neurotransmitter precursors in a syncytial epithelium.

1. Tegumental transport of choline at concentrations ranging from 0.005-5.0 mM provided no evidence for saturable, carrier-mediated entry of this amine in the tegument of the rat tapeworm (Hymenolepis diminuta). 2. In contrast, the large neutral amino acid tryptophan appears to be taken up via a high-affinity transporter. In the 1st quartile of 17-day-old tapeworms (Km = 0.033 mM, Vmax = 0.7 nmol.min-1.g-1), in the 2nd quartile (Km = 0.015 mM, Vmax = 0.3 nmol.min-1.g-1), in the 3rd quartile (Km = 0.022 mM, Vmax = 0.5 nmol.min-1.g-1) and in the 4th quartile (Km = 0.025 mM, Vmax = 0.5 nmol.min-1.g-1) saturable tryptophan transport was kinetically characterized. 3. The non-saturable diffusion component (Kd) for tryptophan transport ranged from 3.8-10.2 microliters.min-1.g-1. 4. These studies suggest choline does not appear to be transported across the tapeworm tegument. Saturable transport of tryptophan via a high-affinity carrier is reported, and no regional variations in indole amino acid uptake were detected.

Animals↗

PubMed1992

Glucose-induced modulation of nutrient influx in Schistosoma mansoni.

The tegumental influx of adenine, adenosine, arginine, choline, histidine, and lysine has been measured in mated and separated male and female Schistosoma mansoni 7-10 wk postinfection. Tissue uptake indices were measured after a brief rinse in either 5 mM glucose or glucose-free saline. Data indicate that schistosomes respond rapidly to this 2-3-sec exposure to glucose-free medium, and lowered uptake rates are observed. Similar studies, measuring cytosine and lysine uptake in Schistosoma japonicum indicate that, in this species also, reduced nutrient influx is seen after a transient exposure to glucose-free medium. It is proposed that these metabolites are not taken up by active transport processes, but rather the effect observed is the consequence of a rapid change in glucose metabolism.

Adenine↗

PubMed1991

Regional modulations in tegumental glucose transporter kinetics in the rat tapeworm.

Comparisons of glucose transporter kinetics in 8-day (Km = 0.34 mM, Vmax = 14 nmole.min-1.g-1), 10-day (Km = 0.46 mM, Vmax = 18 nmole.min-1.g-1), the first quartile of 17-day (Km = 0.51 mM, Vmax = 21 nmole.min-1.g-1), and the first quartile of 32-day (Km = 0.33 mM, Vmax = 39 nmole.min-1.g-1) rat tapeworms (Hymenolepis diminuta) suggest maximal velocities may vary with age. A gradient in glucose transporter density is suggested in the rat tapeworm by changes in the estimated transporter Vmax in the first through fourth quartiles. Alterations in the physiological efficiency (as indicated by the Vmax/Km ratio) and permeability (indicated by the unsaturated permeability-area product) of the glucose transporter were determined to be significantly greater in the first quartile than in other quartiles of 17-day hymenolepids. A similar trend was apparent in older (32-day) worms. In tapeworms maintained for 30 min in glucose-free medium, maximal velocities were highest in the anterior (first) quartile, and reductions were seen in successive second, third, and fourth quartiles. When worms were maintained in a medium containing 11 mM glucose, maximal velocities were about twofold greater, but the Vmax increased in each successive quartile. The apparent half-saturation constants, which indicate that concentration of external glucose at which half of the glucose transporter proteins are occupied, are reduced approximately 50% in tapeworms maintained in glucose-free medium. These studies demonstrate that regional differences exist in the glucose transporter of the rat tapeworm, analogous to the intestinal glucose gradient. Furthermore, substrate-induced modulations in the transporter may also exhibit independent regional variability.

Animals↗

PubMed1990

Glucose utilization rates are linked to the internal free glucose gradient in the rat tapeworm.

Hymenolepis diminuta is able to acquire plasma-borne glucose 3-O-[14C]methylglucose in vivo. Free glucose concentrations estimated for this helminth in vivo are comparable to that of the host intestine. Both in vivo and in vitro examinations indicate that the scolex-neck regions (first quartile) of this tapeworm have the highest glucose content, and an anterior-posterior gradient along the second, third, and fourth quartiles was observed. Substrate concentration was rate affecting for glucose utilization rates (measured as substrate depletion from the medium in vitro). Glucose utilization per minute exceeds glucose content by a factor of more than 5. The half-life of glucose was about 10 sec, emphasizing that sugar metabolism is a very rapid process. In addition, utilization was highest in the first quartile and decreased in succession in the second, third, and fourth quartiles. It is concluded that while the exogenous glucose concentration remains stable, regional differences in glucose utilization rates are linked (R = 0.98; P less than 0.01) to free glucose content in H. diminuta.

Animals↗

PubMed1988

Oltipraz-induced reduction in schistosomal glucose utilization rates.

The rate of phosphorylation of 2-deoxyglucose (2DG) was determined by sequential pulsing of schistosomes (male and female Schistosoma mansoni) with [3H- and 14C]-2-deoxy-D-glucose. The relative phosphorylation rate of 2-[3H]-2DG to 1-[14C]-D-glucose (i.e. the phosphorylation coefficient) was also measured in male and female schistosomes. Even though 2DG is taken up more rapidly than glucose, it is phosphorylated at a much slower rate in S. mansoni. Mated schistosomes phosphorylate 2DG and glucose at a greater rate than do unmated worms. In contrast, the phosphorylation coefficient is greater in separated than mated schistosomes. In schistosomes exposed to oltipraz for short time periods (6 min, at a concentration of 10 micrograms/ml) glucose utilization rates were significantly reduced in (both mated and separated) female S. mansoni and by a similar magnitude (not significant) in males.

Animals↗

PubMed1988

Tegumental glucose permeability in male and female Schistosoma mansoni.

Tegumental hexose transporters have been kinetically characterized in mated and separated male and female Schistosoma mansoni 8-12 wk postinfection. Significant gender-specific differences in Km and Vmax were observed. In mated males, the estimated constants (mean +/- SE) were: Km = 0.63 +/- 0.31 mM, Vmax = 0.93 +/- 0.44 nmol/mg worm water/min, and the Kd = 0.25 +/- 0.09 microliter/mg worm water/min. In mated females the kinetics were: Km = 0.99 +/- 0.40 mM, Vmax = 1.22 +/- 0.42 nmol/mg worm water/min, and Kd = 0.60 +/- 0.14 microliter/mg worm water/min. The influx of 2-deoxy-D-glucose and 3-O-methylglucose has been similarly characterized; these analogs share the same glucose transporter in male and female schistosomes. 2-Deoxy-D-glucose has a higher affinity, and 3-O-methylglucose a lower affinity, than does glucose. Because mated male schistosomes supply glucose to female partners, similarities between the free glucose concentration of the male and the affinity of the transporter determined for mated female schistosomes suggest that male-to-female transfer may be a potentially rate-limiting step in glucose utilization by the female. Permeability x surface are (PS) products and Vmax/Km ratios were significantly elevated in mated schistosomes, suggesting that the transporter is primarily localized to the dorsal surface of the male. Gender- and mating-specific analyses of PS products indicate that tegumental permeability to glucose is significantly increased in mated schistosomes, and compares very favorably to that of the host liver.

3-O-Methylglucose↗

PubMed1987

Comparative glucose utilization rates in separated and mated schistosomes.

The rate of phosphorylation of 2-deoxyglucose (2DG) was determined by sequential pulsing of schistosomes (Schistosoma mansoni, S. japonicum, and S. haematobium) with 3H- and 14C-labeled 2-deoxy-D-glucose. Subsequent column chromatographic separation of the neutral [3H]2DG and [14C]2DG from the 3H- and 14C-labeled 2-deoxy-D-glucose 6-phosphate permitted estimation of the quantity of [3H]2DG phosphorylated in 2 min, and the proportion of [14C]2DG phosphorylated in 1 min; thus a phosphorylation rate was determined from a single tissue sample. The relative phosphorylation rate of 2-[3H]2DG to D-1-[14C]glucose (i.e., the phosphorylation coefficient) was also measured in male and female schistosomes. It was demonstrated that even though 2DG is taken up more rapidly than glucose, it is phosphorylated at a much slower rate in both S. mansoni and S. japonicum. In both of these species, mated males phosphorylate 2DG and glucose at a greater rate than do unmated males. Similarly, mated females phosphorylate and consume more glucose than do separated females. In contrast, the phosphorylation coefficient is greater in separated than in mated schistosomes. Intraspecific comparisons suggest that, at reduced substrate concentrations, glucose utilization rates are higher in S. japonicum, intermediate in S. mansoni, and lower in S. haematobium.

Animals↗

PubMed1986

Nutrient transport and the blood-brain barrier in developing animals.

Structural alterations in the development of the blood-brain barrier (BBB) can be seen in capillary profiles from the rat cortex. The neonatal luminal membrane is amplified with irregular folds, a possible adaptation to reduced cerebral blood flow rates. By 21 days the capillaries have resolved to a smooth-surfaced, adult-like appearance. Developmental alterations in the basement membrane, tight junctions, capillary seams, Golgi, pinocytotic vesicles, and cytoplasmic thickness are observed. Two studies have addressed developmental modulations in BBB polarity; both indicate that brain-to-blood transport mechanisms that were inoperative in the early neonatal rat become functional in weanlings. Six of the seven major independent BBB nutrient transport systems that regulate plasma-to-brain uptake have been kinetically characterized in the newborn rabbit, and comparisons have been made in the weanling (28-day-old) rabbit. All of these saturable transport systems are operative at birth, which suggests that the immature rabbit has a mature BBB with respect to regulation of nutrients. Purine base permeability, affinity, and uptake velocities are virtually unchanged during postnatal development. Subtle alterations in amino acid and amine transport were suggested by the lower-affinity (high-capacity) transport mechanisms characterized in the newborn as compared to the 28-day-old BBB. Under conditions of elevated plasma levels (typical of the neonate), these higher-capacity mechanisms would facilitate a relative increase in metabolite influx to the developing brain. Significant differences in kinetics were also observed for the monocarboxylic acid and hexose transport systems in the absence of developmental changes in permeability times surface area products. A low-affinity, high-capacity monocarboxylic acid transport system operates at birth. It supplies the developing brain with increased quantities of ketone bodies, but is seen as a high-affinity, low-capacity mechanism in the 28-day-old rabbit. Concomitantly, the higher-affinity glucose carrier defined in newborn rabbits modulates, and by 28 days becomes a lower-affinity, high-capacity mechanism capable of delivering about 2 mumol X min-1 X g-1 of glucose to the (anesthetized) brain.

Aging↗

PubMed1986

Epilepsy and the blood-brain barrier.

A concern for the possible role of the blood-brain barrier (BBB) in the epilepsies was based on ultrastructural studies that demonstrated increased micropinocytosis in cerebral capillaries during seizures. Continued interest in the structure of the BBB has led to the demonstration that, in human psychomotor epilepsy, there is a thickening of the capillary basement membrane. These studies also suggest that an increase in capillary mitochondria and interendothelial tight junctions may characterize seizure-traumatized brain regions. These studies forecast an increased interest and understanding of the ultrastructural events associated with capillaries in seizure states. Additional focus on the BBB comes from the clinical use of anticonvulsant drug levels in the control and treatment of seizures. Debate as to whether free drug levels are appropriate continues. The brain capillary is the interface between blood-borne drug and the target site, and thus an increased understanding of the events associated with brain-plasma exchange has been sought. The concept that only that fraction of drug that is freely dialyzable is available for equilibration across the BBB is not supported by recent studies, which demonstrate that protein-bound ligands are able to dissociate and gain access to the brain in the course of a single capillary transit. It has been established that albumin-bound fatty acids, steroids, and anticonvulsant drugs more readily distribute into tissues than previously believed. Thus, traditional free drug hypotheses need to be expanded to account for the fact that dissociation constants measured in vitro are not the same as those measured in vivo. The BBB also regulates nutrient availability to the brain, and under normal conditions excess substrate is made available to the brain for metabolism. Indirect evidence is available to suggest that during seizures, BBB transport may indeed be the rate-limiting step. Specifically, glucose availability to the seizing brain may be restricted to such a degree that brain glucose utilization rates are no longer independent of plasma glucose levels. If it can be proven that BBB transport is the rate-limiting step during seizures, then it would be possible to augment brain glucose utilization rates by increasing plasma glucose levels. In addition, a depression of brain glucose utilization could be achieved by inducing hypoglycemia. It is not fully understood whether BBB rate limitation would persist postically, nor is it known whether BBB alterations may be global or restricted to the seizure focus.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

PubMed1985

Schistosoma mansoni, S. japonicum, and S. haematobium: permeability to acidic amino acids and effect of separated and unseparated adults.

Permeability of the tegument of male and female Schistosoma mansoni was measured in vitro and a comparison was made between copulating and separated worms. In unpaired (separated) schistosomes, a carrier-mediated (selective) transport system for acidic amino acids was demonstrated. Males and females exhibited similar uptake rates for aspartate and glutamate. Half-saturation constants for aspartate (males, 0.035 +/- 0.008 mM; females, 0.026 +/- 0.006 mM) and glutamate (males, 0.010 +/- 0.007 mM; females, 0.015 +/- 0.004 mM) were determined for separated worms only. Time-course studies provided estimates of aspartate influx rates in males (7.3 pmol min-1 worm-1) and females (2.3 pmol min-1 worm-1). The most dramatic observation, however, was that, in copula, neither male nor female schistosomes took up acidic amino acids, but may have excluded these compounds. Thus, this ouabain-insensitive, mediated mechanism was operational only when the worms were unmated. In S. japonicum, no uptake of glutamate was observed in either mated or separated males and females. In S. haematobium, saturable uptake of aspartate was apparent in both mated and unmated males and females, indicating that species-specific differences in uptake of acidic amino acids existed. These studies indicate the need for cautious interpretation of data obtained from in vitro analyses of separated male and female mansonian schistosomes, and that such conditions may not reflect in vivo or in copula function.

Animals↗